[A novel VEGF-independent antiangiogenic therapy targeting the CD160 receptor].

Authors :: Le Bouteiller P
Tabiasco J
Giustiniani J
Bensussan A
Source :: Medecine sciences : M/S [Med Sci (Paris)] 2012 Jan; Vol. 28 (1), pp. 37-8. Date of Electronic Publication: 2012 Jan 27.
Publication Year :: 2012

Subjects :: Animals
Antibodies, Monoclonal immunology
Antibodies, Monoclonal therapeutic use
Antigens, CD immunology
Antineoplastic Agents, Alkylating therapeutic use
Colonic Neoplasms drug therapy
Combined Modality Therapy
Corneal Neovascularization drug therapy
Cyclophosphamide therapeutic use
Drug Screening Assays, Antitumor
Fibrosarcoma blood supply
Fibrosarcoma drug therapy
Fibrosarcoma immunology
GPI-Linked Proteins antagonists & inhibitors
GPI-Linked Proteins immunology
Humans
Melanoma, Experimental blood supply
Melanoma, Experimental drug therapy
Melanoma, Experimental immunology
Mice
Neovascularization, Pathologic drug therapy
Neovascularization, Pathologic immunology
Rabbits
Receptors, Immunologic immunology
Species Specificity
Angiogenesis Inhibitors pharmacology
Antibodies, Monoclonal pharmacology
Molecular Targeted Therapy
Receptors, Immunologic antagonists & inhibitors

Full Text Access

Tools